Physician profile
Radha Syed
NPI 1790707263
$14,525.33
in general payments reported to CMS, 2019-2025
33 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $876 · 2021: $1,172 · 2022: $1,381 · 2023: $1,420 · 2024: $7,780 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $2,846 · Travel and Lodging: $1,795 · Education: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $2,846.37 |
| Travel and Lodging | $1,794.59 |
| Education | $660.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $6,829.39 | 2019-2024 | Endosee |
| Abbvie INC. | $1,299.62 | 2019-2023 | Lo Loestrin Fe |
| Exeltis, USA INC. | $940.55 | 2020-2025 | Slynd |
| Millicent US INC | $820.09 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $500.68 | 2021-2025 | |
| Amgen INC. | $475.32 | 2019-2023 | Lumakras |
| Evofem Biosciences, INC. | $472.91 | 2021-2025 | Phexxi, Solosec, Phexx |
| Astrazeneca Pharmaceuticals LP | $364.02 | 2022-2024 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $343.41 | 2020-2023 | Opdivo |
| Astellas Pharma US INC | $340.30 | 2023-2025 | Veozah |
| Lupin INC. | $242.15 | 2019-2021 | |
| Incyte Corporation | $198.76 | 2019-2020 | |
| Hologic Sales and Service, LLC | $191.51 | 2022-2024 | Omni Hysteroscope, Novasure, Acessa Provu System |
| Baxter Healthcare | $143.72 | 2024 | Starling System |
| Organon LLC | $140.36 | 2021-2024 | Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $138.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.68 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $135.27 | 2021-2023 | Keytruda |
| Daiichi Sankyo INC. | $125.00 | 2022 | |
| Avion Pharmaceuticals | $106.92 | 2021-2022 | |
| Pfizer INC. | $87.58 | 2021-2024 | |
| Channel Medsystems, INC. | $76.38 | 2023 | |
| Sumitomo Pharma America, INC. | $73.41 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $54.44 | 2022-2025 | |
| Allergan, INC. | $54.05 | 2020-2021 | |
| Qol Medical, LLC | $48.77 | 2022 | |
| Myovant Sciences INC. | $38.46 | 2021 | |
| Vertical Pharmaceuticals, LLC | $33.25 | 2019 | |
| Agile Therapeutics, INC. | $28.41 | 2021-2022 | |
| Radius Health, INC. | $24.62 | 2021 | |
| Duchesnay USA Incorporated | $23.51 | 2019 | |
| Roche Diagnostics Corporation | $18.56 | 2019 | |
| Alfasigma USA, INC. | $16.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.